Actively Recruiting
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
Led by Leiden University Medical Center · Updated on 2026-02-13
300
Participants Needed
1
Research Sites
337 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
CONDITIONS
Official Title
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with suspicion or diagnosis of primary or recurrent epithelial ovarian cancer with an indication for surgery, chemotherapy, and/or immunotherapy.
- Age 18 years or older.
- WHO performance status 0 to 2.
- Accessible for treatment and follow-up.
- Signed written informed consent.
You will not qualify if you...
- Other active malignancy in the past 5 years except treated non-melanoma skin cancer.
- Known severe infection such as HIV or hepatitis A, B, or C.
- Receiving immune suppressive treatment.
- Medical or psychological condition that may prevent completion of the study or signing informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Leiden University Medical Center
Leiden, Netherlands
Actively Recruiting
Research Team
J
Judith R Kroep, MD PhD
CONTACT
A
A F de Groot, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here